This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q85.0 / Special Copayment Reduction: V156 / re-certification cycle: 5 years |
| B. Synonyms | Von Recklinghausen disease, neurofibromatosis (nonmalignant) type 1, neurofibromatosis (nonmalignant) type 2 |
| C. Adult onset | Presents in childhood with café-au-lait macules; neurofibromas increase and neurological complications progress in adulthood |
| 1. History | Described by von Recklinghausen in 1882; history of the isolation of the NF1/NF2 genes |
| 2. Epidemiology | NF1: 1/2,500–3,000 births; NF2: 1/25,000–40,000 births |
| 3. Etiology and genetics | NF1: 17q11.2 neurofibromin; NF2: 22q12 merlin; autosomal dominant |
| 4. Pathophysiology | RAS-MAPK hyperactivation; Hippo-YAP pathway abnormality; mechanism of cellular hyperproliferation |
| 5. Clinical features | Café-au-lait macules, neurofibromas, Lisch nodules, acoustic schwannomas, etc. |
| 6. Diagnostic criteria | NIH diagnostic criteria (1987); 2021 revised criteria; genetic testing |
| 7. Differential diagnosis | LEOPARD syndrome, Legius syndrome, spinal muscular atrophy, etc. |
| 8. Laboratory and imaging findings | MRI, audiometry, ophthalmologic examination, molecular genetic testing |
| 9. Treatment | MEK inhibitor (selumetinib), surgery, radiotherapy |
| 10. Complications | Malignant peripheral nerve sheath tumor (MPNST), optic glioma, cognitive impairment |
| 11. Prognosis | NF1 mean life expectancy shortened by about 8–15 years; MPNST 5-year survival 20–50% |
| 12. Prevention | Genetic counseling, preimplantation genetic diagnosis, regular follow-up examinations |
| 13. References | Legius E et al. (2021) Revised diagnostic criteria for neurofibromatosis type 1 and 9 other papers |
The clinical entity of neurofibromatosis was first formally described in medical history in 1882 by the German pathologist Friedrich Daniel von Recklinghausen. He systematically observed patients in whom multiple cutaneous neurofibromas and café-au-lait pigmented macules coexisted, and was the first to define them as tumors of neural origin; the disease subsequently came to be called 'von Recklinghausen disease' after him. However, observations of this disease existed well before that. Fragmentary descriptions of patients with skin tumors are found in 16th-century European medical literature, and the 18th-century anatomist Marc Aurelio Severino recorded similar cases. In 1918, the Berlin surgeon Wilder Penfield drew attention to the diversity of nervous system involvement.
Until the mid-20th century, neurofibromatosis was considered a single disease, but in 1981 the US National Institutes of Health (NIH) recommended its formal separation into two subtypes with clearly distinct clinical and genetic features, type 1 (NF1) and type 2 (NF2). Subsequently, at the 1987 NIH Consensus Development Conference, clinical diagnostic criteria were established that are still widely used today.
Molecular genetic discoveries advanced rapidly in the 1990s. The NF1 gene was cloned on chromosome 17q11.2 in 1990 by two independent research teams (Viskochil et al., Wallace et al.), and its product, neurofibromin, was shown to perform a tumor suppressor function as a RAS-GTPase-activating protein (GAP). The NF2 gene was discovered simultaneously at 22q12 in 1993 by two groups (Rouleau et al., Trofatter et al.), and its product, merlin (schwannomin), was identified as an ezrin-radixin-moesin (ERM) family cytoskeletal protein.
Since the 2000s, the spectrum has expanded beyond NF1 and NF2 to include schwannomatosis (SMARCB1/LZTR1 mutations), segmental NF1, and others, and in 2021 an international expert consortium revised the NF1 diagnostic criteria again to formally include molecular genetic findings. In Korea, where the rare disease Special Copayment Reduction system has been introduced, all nonmalignant neurofibromatosis is managed under code V156.
Neurofibromatosis type 1 (NF1) is the most common single-gene neurocutaneous syndrome, with a worldwide birth frequency reported at about 1/2,500–3,000. There are no significant differences by sex or ethnicity, and a similar incidence is estimated in Korea. According to Health Insurance Review & Assessment Service (HIRA) data, patients registered for the Special Copayment Reduction in Korea number in the thousands, but considering unregistered mild cases, the actual prevalence is expected to be higher.
Neurofibromatosis type 2 (NF2) is much rarer than NF1, with a birth frequency estimated at 1/25,000–40,000. The worldwide prevalent population of NF2 is estimated at about 100,000–200,000. In terms of age distribution, 95% of patients with NF1 meet at least 2 of the 6 NIH criteria by age 8, and NF2 presents clinically mainly in the late teens to early 30s with acoustic schwannomas (bilateral vestibular schwannomas).
In NF1, new (de novo) mutations account for about 50% of all cases, because the NF1 gene is one of the largest genes in the human genome (57 exons, more than 350 kb) with a high mutation frequency. In NF2, the de novo rate is about 50%. This high rate of new mutations is an important consideration in genetic counseling.
The lifetime risk of malignant peripheral nerve sheath tumor (MPNST) in patients with NF1 is 8–13%, more than 1,000 times higher than in the general population. Optic pathway glioma occurs in 15–20% of patients with NF1, and less than half of these become symptomatic. These complication incidence data form the basis for establishing surveillance protocols.
The causative gene of NF1 is located on chromosome 17q11.2 and consists of 57 exons (58 coding exons) spanning a genomic region of more than 350 kb. The mRNA is 11–13 kb, and its protein product, neurofibromin, is a cytoplasmic protein of 2,818 amino acids with a molecular weight of about 327 kDa. The central functional domain of neurofibromin is the RAS GTPase-activating protein-related domain (GRD; aa 1,198–1,530), which performs the GAP function of converting active RAS-GTP to inactive RAS-GDP. When a pathogenic mutation occurs in the NF1 gene, neurofibromin function is lost and RAS-GTP levels rise persistently, leading to hyperactivation of the MAPK/ERK, PI3K/AKT, and mTOR pathways and release of the inhibition of cell proliferation.
The mode of inheritance of NF1 is autosomal dominant, with nearly complete penetrance, but the phenotype varies markedly even within the same family (variable expressivity). This phenomenon is explained by the combined action of somatic mutation of the second allele (two-hit model), modifier genes, and environmental factors. Mutation types are diverse, including nonsense mutations, frameshifts, splicing variants, deletions, and insertions, and there are reports that mutations in exon 17 and exons 1–7 are associated with more severe phenotypes. Large deletions (microdeletions) around 17q11.2 account for about 5–10% of all NF1 mutations, and in these cases cognitive impairment is more severe and the neurofibroma burden is greater.
The causative gene of NF2 is located on chromosome 22q12.2 and, with 17 exons and a 4.4 kb mRNA, encodes the 595-amino-acid protein (molecular weight 69 kDa) merlin (schwannomin). Merlin is an ERM family protein that links cell-surface receptors to the actin cytoskeleton and functions as an upstream regulator of contact inhibition and the Hippo-YAP signaling pathway. NF2 mutations are also inherited in an autosomal dominant manner, but are expressed as schwannomas or meningiomas through a tissue-specific second hit. Somatic mosaicism is observed in about 25–30% of NF2, in which case symptoms may be mild and the age of onset later.
The core of NF1 pathophysiology is persistent hyperactivation of the RAS-MAPK signaling pathway. Neurofibromin normally promotes the RAS-GTP→RAS-GDP conversion to control cell proliferation signals. When neurofibromin function is lost, intracellular RAS-GTP accumulates, the RAF-MEK-ERK cascade is upregulated, and cell-cycle progression, cell survival, and angiogenesis increase. The PI3K-AKT-mTOR axis is also activated, increasing protein synthesis and inhibiting autophagy.
The two-hit model applies to neurofibroma formation. When somatic loss of the second allele (LOH) occurs in Schwann cells carrying a heterozygous germline mutation, proliferation increases sharply. However, Schwann cells alone do not form neurofibromas; interaction with cells of the surrounding microenvironment, such as mast cells, fibroblasts, and endothelial cells, is essential. NF1-heterozygous mast cells respond hypersensitively to stem cell factor (SCF) and oversecrete cytokines that promote Schwann cell growth, which induces neurofibroma growth.
In NF2, loss of merlin causes dysregulation of the Hippo-YAP pathway. In normal cells, merlin activates the LATS1/2 kinases, which phosphorylate and degrade the YAP/TAZ transcription factors. When merlin is lost, YAP/TAZ translocate into the nucleus and bind the TEAD transcription factors, upregulating cell proliferation and survival genes. In addition, merlin is involved in tumor suppression through multiple pathways, such as inhibition of ErbB2/ErbB3 receptor signaling and inhibition of the CRL4-DCAF1 E3 ubiquitin ligase, so targeted treatment of a single pathway alone has limitations.
Café-au-lait macules (CALMs) are the earliest clinical finding of NF1, appearing at birth or within the first 1–2 years of life. Under the NIH criteria, 6 or more macules of 5 mm (prepubertal) or 15 mm (postpubertal) or more in diameter meet 1 diagnostic criterion. The macules are distributed mainly on the trunk and limbs and are rare on the face and scalp. Freckle-like pigmentation around the axillae or groin (axillary/inguinal freckling, Crowe sign) is also characteristic and usually appears from around age 3–5.
Neurofibromas are benign tumors originating from Schwann cells of peripheral nerves and occur in more than 95% of patients with NF1. There are three subtypes: cutaneous, subcutaneous, and plexiform. Cutaneous and subcutaneous types appear from around puberty and increase in number in adulthood, reaching tens to thousands. Plexiform neurofibromas are diffuse tumors that grow along multiple nerve bundles, are present from birth, and grow rapidly at a young age. The plexiform type carries a risk of transformation into malignant peripheral nerve sheath tumor (MPNST).
Lisch nodules are melanocytic hamartomas formed in the iris and are observed on slit-lamp examination. The age-dependent cumulative incidence in patients with NF1 is 55% at age 8 and more than 90% in adults. They do not affect vision but have great diagnostic value.
Optic pathway glioma (OPG) occurs in 15–20% of patients with NF1 and is usually distributed along the optic nerve, optic chiasm, and optic tract. Histologically, most are WHO grade I pilocytic astrocytomas, and in children aged 5 years or younger they can cause decreased vision, proptosis, and strabismus.
Among neurological abnormalities, cognitive impairment is the most common, with specific learning disabilities (reading, mathematics), attention-deficit/hyperactivity disorder (ADHD), and executive dysfunction reported in about 50–80% of patients. Scoliosis occurs in about 10–30%, and other tumors such as intracranial meningiomas and brainstem gliomas can also occur.
The characteristic finding of NF2 is bilateral vestibular schwannoma, which initially presents with tinnitus and hearing loss and, as it progresses, is accompanied by balance disturbance and facial nerve palsy. The mean age at diagnosis is 18–24 years. Meningiomas occur in 50–80% of patients with NF2 and appear as multiple lesions together with spinal schwannomas. Ependymomas of the brainstem and spinal cord are also common.
The diagnosis of NF1 is based on the 1987 NIH consensus criteria, which were later supplemented with molecular genetic findings in the 2021 revised criteria. Under the NIH criteria, the diagnosis is made when 2 or more of the following 7 items are met: ① 6 or more CALMs of 5 mm or more in diameter; ② 2 or more neurofibromas or 1 or more plexiform neurofibromas; ③ axillary or inguinal freckling; ④ optic glioma; ⑤ 2 or more Lisch nodules; ⑥ distinctive bone dysplasia (sphenoid dysplasia, thinning of long bone cortex, etc.); ⑦ a first-degree relative with confirmed NF1.
Under the 2021 revised criteria (Legius et al.), the diagnosis is also established when a pathogenic NF1 variant is confirmed by molecular genetics. However, to differentiate from Legius syndrome (SPRED1 mutation), active molecular testing is recommended when only CALMs and freckling are present.
The NF2 diagnostic criteria (Manchester criteria) are: ① bilateral vestibular schwannomas; or ② a first-degree relative with confirmed NF2 + unilateral vestibular schwannoma or 2 of schwannoma, meningioma, ependymoma, or juvenile posterior subcapsular cataract; or ③ unilateral vestibular schwannoma + 2 of schwannoma, meningioma, ependymoma, or juvenile posterior subcapsular cataract; or ④ 2 or more meningiomas + unilateral vestibular schwannoma or 2 of schwannoma, ependymoma, or juvenile posterior subcapsular cataract, among others.
Genetic testing is performed by NGS-based panels or whole-genome sequencing, with large deletions/duplications supplemented by MLPA. It is particularly useful when the clinical diagnosis is uncertain, when a de novo mutation is suspected, or when preimplantation genetic diagnosis (PGT-M) is planned.
Legius syndrome (SPRED1 mutation) resembles NF1 in CALMs and axillary freckling but lacks neurofibromas, Lisch nodules, optic glioma, and bone dysplasia. It can be differentiated by molecular testing.
LEOPARD syndrome (RASopathy, PTPN11/RAF1 mutations) presents as a combination of multiple lentigines, ECG abnormalities, facial abnormalities, pulmonary stenosis, genital abnormalities, growth retardation, sensorineural hearing loss, and others.
Carney complex is a combination of CALMs, myxomas, and endocrine tumors caused by PRKAR1A mutations and needs to be differentiated.
Segmental NF1 consists of localized CALMs and neurofibromas due to somatic mosaicism, with no systemic hereditary risk.
Schwannomatosis is multiple schwannomas without NF2, caused by SMARCB1 or LZTR1 mutations, and differs from NF2 in the absence of vestibular schwannomas.
McCune-Albright syndrome is characterized by large CALMs with irregular borders, polyostotic fibrous dysplasia, and endocrine abnormalities.
Brain and spinal MRI: in patients with NF1, hyperintense lesions on T2/FLAIR (unidentified bright objects, UBOs) appear in the basal ganglia, cerebellum, and brainstem, reflecting ectopic myelination or abnormal myelination. Most disappear after puberty. MRI is also essential for evaluating optic gliomas and plexiform neurofibromas. In NF2, gadolinium contrast-enhanced MRI of bilateral acoustic neuromas is the standard diagnostic imaging.
Ophthalmologic examination: slit-lamp examination identifies Lisch nodules and posterior subcapsular opacity cataracts (NF2). When optic glioma is suspected, visual evoked potentials (VEP), optical coherence tomography (OCT), and visual field testing are performed.
Hearing tests: in NF2, pure-tone audiometry (PTA), auditory brainstem response (ABR), and speech recognition testing are performed, and vestibular function tests (caloric test, VEMP) are also used as a supplement.
Molecular genetic testing: NGS-based multigene panel or single-gene sequencing. Large deletions/duplications are detected by MLPA. When mosaicism is suspected, DNA from cultured skin fibroblasts or deep sequencing is used.
Tissue biopsy: core biopsy is performed when MPNST transformation of a plexiform neurofibroma is suspected (rapid growth, pain, high FDG-PET uptake). FDG-PET/CT is useful for assessing the whole-body burden of plexiform neurofibromas and for screening for MPNST.
Neurocognitive testing: in pediatric patients with NF1, early assessment of learning disabilities with standardized neurocognitive and attention tests such as the K-WISC, WCST, and BRIEF is recommended.
The first FDA-approved targeted therapy for progressive plexiform neurofibromas in NF1 is selumetinib (Koselugo®), approved in 2020 for symptomatic, progressive plexiform neurofibromas in pediatric patients with NF1 aged 2 years and older. Selumetinib, a MEK1/2 inhibitor, showed a response rate of about 66% (tumor volume reduction of 20% or more) in the SPRINT-NF1 phase II randomized controlled trial. The dose is 25 mg/m² bid based on body surface area, and the main adverse reactions are acneiform dermatitis, gastrointestinal disturbance, cardiomyopathy, and visual abnormalities.
For optic glioma treatment, carboplatin + vincristine combination chemotherapy is the first-line standard when symptoms and decline in vision progress, and recently vemurafenib and dabrafenib + trametinib combination therapy have shown efficacy in BRAF V600E-mutant optic gliomas. Radiotherapy is avoided as much as possible in children because of the risk of secondary malignancy.
MPNST is the most important complication determining the prognosis of patients with NF1, and wide surgical resection (R0 margin) is the standard where possible. Adjuvant radiotherapy and chemotherapy (ifosfamide-based) are also given. Combination strategies of MEK inhibitors and CDK4/6 inhibitors are currently being studied in clinical trials.
In NF2, treatment of vestibular schwannomas is individualized among observation, surgery (retrosigmoid approach, translabyrinthine approach), and Gamma Knife radiosurgery (SRS) according to tumor size, hearing status, and patient age. Bevacizumab (anti-VEGF) has been confirmed to be effective in suppressing tumor growth and preserving hearing in NF2-related vestibular schwannomas and is used clinically. Results of NF2 clinical trials of ErbB inhibitors (lapatinib, erlotinib) are partial, and merukinib (merlin), FAK inhibitors, and others are under study.
Malignant peripheral nerve sheath tumor (MPNST) is the most serious complication of NF1, with a lifetime risk of 8–13%. Risk factors for transformation of an existing plexiform neurofibroma into MPNST are an increase in the volume of internal plexiform neurofibromas, the onset of pain, and elevated FDG-PET SUVmax. MPNST frequently recurs locally and metastasizes distantly, with a poor 5-year survival of 20–50%.
Cognitive impairment and learning disabilities occur in 50–80% of patients with NF1 and include reading disorders, mathematics disorders, ADHD, executive dysfunction, and autism spectrum symptoms. This is interpreted as the result of RAS-ERK hyperactivation due to NF1 gene heterozygosity affecting neuroplasticity and synaptic function. Appropriate educational support and drug treatment (methylphenidate) help improve ADHD symptoms.
Vascular dysplasia is a relatively rare but serious complication of NF1, including renovascular hypertension due to renal artery stenosis, coronary artery abnormalities, and cerebral aneurysms. Undiagnosed renovascular hypertension in pediatric NF1 can be a risk factor for stroke.
Scoliosis occurs in 10–30%; dystrophic scoliosis progresses more rapidly than ordinary scoliosis and often requires surgical correction. Tibial dysplasia and pseudarthrosis of the tibia are also rare but serious orthopedic complications.
In NF2, the main complications are hearing loss, facial nerve palsy, increased intracranial pressure due to multiple meningiomas, and spinal cord compression.
Although NF1 is classified as nonmalignant, the diversity and severity of its complications significantly affect patients' life expectancy and quality of life. In large cohort studies, the median age at death of patients with NF1 is shortened by about 8–15 years compared with the general population, and the main causes of death are MPNST (most frequent), vascular complications, brain tumors, and others. MPNST accounts for about 60% of deaths in NF1.
About half of optic gliomas arising in childhood regress spontaneously, but the rest may progress and cause permanent visual impairment. Early diagnosis and periodic ophthalmologic follow-up are important for preserving vision.
Cognitive impairment mostly does not reach the level of intellectual disability, but it continues to affect academic achievement, social functioning, and occupational adjustment. Appropriate educational and vocational rehabilitation support is needed.
The prognosis of patients with NF2 is closely related to early detection of vestibular schwannomas and the success of hearing-preserving treatment. When multiple brain and spinal tumors are present, the need for repeated surgery and radiotherapy is high, and the reduction in quality of life can be severe. With the introduction of systemic treatments such as bevacizumab, hearing preservation and improved quality of life have been reported in some patients with NF2.
Because neurofibromatosis is a genetic disease, fundamental primary prevention is currently not possible. However, the following strategies are recommended to reduce morbidity and mortality through early detection of complications.
Genetic counseling is essential for patients with NF1/NF2 and their families. Explain that with autosomal dominant inheritance the risk of transmission from an affected parent to a child is 50%, and that the de novo mutation rate is 50%. Patients planning pregnancy can select embryos for carrier status through preimplantation genetic diagnosis (PGT-M) or prenatal diagnosis (amniocentesis/chorionic villus sampling + molecular genetic testing).
Regular follow-up protocol: pediatric patients with NF1 undergo annual ophthalmologic examination (optic glioma surveillance), blood pressure measurement (renovascular hypertension), neurocognitive assessment, and spinal examination. Adults undergo annual examination of skin tumors with dermatology and neurology consultation, and MRI when necessary. Patients with plexiform neurofibromas are monitored for malignant transformation with whole-body MRI or FDG-PET/CT every 2–3 years.
Education and vocational rehabilitation: when learning disabilities or ADHD are identified early, special education, speech therapy, and behavioral therapy are started, and in adulthood, links to vocational adjustment support services are provided.
Psychological support: because anxiety and depressive symptoms due to changes in body image (multiple cutaneous neurofibromas) and uncertain prognosis are common, psychiatric consultation and participation in patient and family support groups are recommended.
Through participation in patient registries and rare disease networks, up-to-date clinical trial information is provided, and integrated management based on a multidisciplinary team (neurology, dermatology, ophthalmology, orthopedics, otolaryngology, genetic counselors, psychologists) is carried out.